Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS Temporarily Transfers Allergy Drug Pemilaston To Alfresa Pharma

This article was originally published in PharmAsia News

Executive Summary

U.S. drugmaker Bristol-Myers Squibb announced Nov. 26 that the company has transferred manufacturing and marketing rights of allergy drug Pemilaston (pemirolast) in Japan to Alfresa Pharma until the end of March 2009. A subsidiary of Alfresa Holdings, Alfresa Pharma has been focusing on allergy drugs and pemirolast will strengthen its product lineup, while Bristol is consolidating resources on its cancer and HIV drug business. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067341

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel